How much revenue does Abbott India make?

Abbott India reported 64.07 billion INR in revenue for fiscal year 2025, up 9.6% from 58.47 billion INR in fiscal year 2024. In Q2 2026 revenue was 17.57 billion INR.

What companies are similar to Abbott India?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Glenmark Pharmaceuticals Limited (GLENMARK.NS), Alkem Laboratories Limited (ALKEM.NS), Biocon Limited (BIOCON.NS), Ipca Laboratories Limited (IPCALAB.NS).

Abbott India Limited (ABBOTINDIA.NS) Stock

About Abbott India Limited

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto,...

At a glance

Abbott India reported revenue of 64.07 billion INR for fiscal year 2025, up 9.6% from fiscal year 2024, and net income of 14.14 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 17.57 billion INR, up 7.6% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.